A Study to Understand How Effective is Tofacitinib When Compared to Other Advanced Treatments in Patients With Rheumatoid Arthritis

Part of paid clinical trials in New York, New York.

Sponsor
Pfizer
Study ID
NCT06418529
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • tofacitinib — DRUG
    New index treatment of tofacitinib
  • tumor necrosis factor inhibitors (TNFi) — DRUG
    New index treatment of TNFi
  • abatacept — DRUG
    New index treatment of abatacept
  • tocilizumab or sarilumab — DRUG
    New index treatment of tocilizumab or sarilumab

Study Details

The purpose of this study is to learn how different types of medicines may improve disease activity in people with rheumatoid arthritis (RA). RA is a kind of joint disease that causes pain and swelling. The study will look at data from a large, US-based group of RA patients who have taken the below medicines: * Tofacitinib * Abatacept * Tocilizumab or sarilumab The study will compare clinical disease activity scores of patients on the different medicines taken. The study will also decide whether some patient traits or disease factors play a role in how medicines may improve disease activity.

Key Dates

Start date
May 15, 2024
Status verified
Jul 2025
Primary completion
Jul 19, 2024
Completion
Jul 19, 2024

Study Design

Enrollment
21,340 participants (actual)

Arms

  • Arm: rheumatoid arthritis
    Patients diagnosed with rheumatoid arthritis

Primary Outcome Measure

Incidence Rate of Low Disease Activity (LDA) or Remission Based on Clinical Disease Activity Index (CDAI) at 6-Months Follow-up: Tofacitinib vs. TNFi [ Time Frame: During 6 month of follow-up post-initiation of tofacitinib or TNFi; retrospective data retrieved, were assembled in this study from 15-May-2024 to 19-July-2024 (approximately 2 months) ]

Locations (1)

FacilityCityStateZIPSite coordinators
PfizerNew YorkNew York10017-

Related coverage on Hipa.ai

Find similar trials in New York, NY

By condition
Rheumatoid arthritis
By specialty
RheumatologyAutoimmune diseaseMusculoskeletal disorders
By research site
Pfizer· New York, NY

Related Studies